Just caught PEN's latest quarterly results and honestly the numbers are solid. Q4 adjusted EPS hit $1.18, beating expectations, and revenues came in at $385.4M with a nice 22.1% year-over-year jump. Full year they did $3.84 in adjusted earnings, up nearly 83% from 2024. Margins expanded too which is always a good sign when you're scaling.

The interesting part though - Boston Scientific already announced they're acquiring them back in January for $374 a share, so PEN stopped giving 2026 guidance. The deal values the company at around $14.5 billion and should close this year pending shareholder approval. Stock's up about 1.7% since the acquisition announcement, currently trading around $344.

Their thrombectomy and embolization products both grew solid double digits, with US markets driving most of the strength. If you're looking to sell PEN at this point you're probably waiting to see if that acquisition price holds or if there's any deal risk. The fundamentals looked good heading into this, but the acquisition kind of puts a ceiling on where the stock can go.